Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1999-02-23
2000-06-27
Schwartzman, Robert A.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
530300, 530350, 435 4, C07K 704, C07K 1447
Patent
active
06080548&
ABSTRACT:
The invention provides human cyclic nucleotide phosphodiesterases (PDE8) and polynucleotides which identify and encode PDE8. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PDE8.
REFERENCES:
Angel, J.B. et al., Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication, AIDS (1995) 9:1137-1144.
Bang, Y.J. et al., Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP, Proc Natl Acad Sci USA (1994) 91:5330-5334.
Banner, K.H. and Page, C.P., Immunomodulatory actions of xantines and isoenzyme selective phosphodiesterase inhibitors, Mondaldi Arch Chest Dis (1995) 50:4,286-292.
Banner, K.H. and Page, C.P., Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma, Eur Respir J (1995) 8:996-1000.
Beavo, Joseph A., Cyclic Nucleotide Phosphodiesterase: Functional Implications of Multiple Isoforms, Physiological Reviews (1995) 75:725-747.
Deonarain, M.P. and Epenetos, A.A., Targeting enzymes for cancer therapy: old enzymes in new roles, (1994) Br J Cancer 70:786-794.
Joulain, C. et al., Influence of polyunsaturated fatty acids on lipid metabolism in human blood mononuclear cells and early biochemical events associated with lymphocyte activation, J Lipid Mediators Cell Signalling (1995) 11:63-79.
Matousovic, K. et al., Inhibitors of Cyclic Nucleotide Phosphodiesterase Isozymes Type-III and Type-IV Suppress Mitogenesis of Rat Mesangial Cells, J Clin Invest (1995) 96:401-410.
Sasaki, H. et al., Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol, European Journal of Pharmacology (1995) 282:71-76.
Sommer, N., The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis, Nature Medicine (1995) 1:244-248.
Thompson, W. J. Cyclic Nucleotide Phosphodiesterases: Pharmacology, Biochemistry and Function, Pharmac Ther (1991) 51:13-33.
Verghese, M.W. et al., Regulation of Distinct Cyclic AMP-Specific Phosphodiesterase (Phosphodiesterase Type 4) Isozymes in Human Monocytic Cells, Molecular Pharmacology (1995) 47:1164-1171.
Hillier, L., et al., Zh47a11.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 415196 5, EST Accession No. W91922.
Bolger et al. (Jan. 1996) Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8. J. Biol. Chem. 271:1065-1071.
Au-Young Janice
Cocks Benjamin G.
Coleman Roger
Fisher Douglas A.
Seilhamer Jeffrey J.
Incyte Pharmaceuticals Inc.
Murry Lynn E.
Schwartzman Robert A.
LandOfFree
Cyclic nucleotide phosphodiesterases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic nucleotide phosphodiesterases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic nucleotide phosphodiesterases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1783036